Lucid Diagnostics マネジメント
マネジメント 基準チェック /34
Lucid Diagnosticsの CEO はLishan Aklogで、 Oct2021年に任命され、 の在任期間は 4.58年です。 の年間総報酬は$ 897.00Kで、 33.4%給与と66.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.91%を直接所有しており、その価値は$ 3.89M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と5.5年です。
主要情報
Lishan Aklog
最高経営責任者
US$897.0k
報酬総額
| CEO給与比率 | 33.44% |
| CEO在任期間 | 4.6yrs |
| CEOの所有権 | 1.9% |
| 経営陣の平均在職期間 | 4.4yrs |
| 取締役会の平均在任期間 | 5.5yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.
ナラティブの更新 • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
新しいナラティブ • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.ナラティブの更新 • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.ナラティブの更新 • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).ナラティブの更新 • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).ナラティブの更新 • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).ナラティブの更新 • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking Alphaナラティブの更新 • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).ナラティブの更新 • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.分析記事 • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.分析記事 • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.分析記事 • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$58m |
| Dec 31 2025 | US$897k | US$300k | -US$71m |
| Sep 30 2025 | n/a | n/a | -US$66m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$71m |
| Dec 31 2024 | US$712k | US$300k | -US$53m |
| Sep 30 2024 | n/a | n/a | -US$52m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$300k | US$300k | -US$53m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$57m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$456k | n/a | -US$56m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$7m | n/a | -US$28m |
報酬と市場: Lishanの 総報酬 ($USD 897.00K ) は、 US市場 ($USD 1.66M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Lishanの報酬は増加しましたが、会社は利益を上げていません。
CEO
Lishan Aklog (59 yo)
4.6yrs
在職期間
US$897,000
報酬
Dr. Lishan Aklog, M.D., serves as an Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. A...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 4.6yrs | US$897.00k | 1.91% $ 3.9m | |
| President & COO | 4.2yrs | US$822.00k | 0.76% $ 1.5m | |
| Chief Financial Officer | 8yrs | US$750.75k | 0.95% $ 1.9m | |
| General Counsel & Secretary | 4yrs | US$759.50k | 0.52% $ 1.1m | |
| Co-Founder & Strategic Advisor | no data | US$924.54k | データなし | |
| Co-founder & Strategic Advisor | no data | データなし | データなし | |
| Co-Founder & Strategic Advisor | no data | データなし | データなし | |
| Co-Founder & Strategic Advisor | no data | データなし | データなし | |
| Chief Technology & Compliance Officer | no data | データなし | データなし | |
| Senior VP & Chief Scientific Officer | 4.6yrs | データなし | データなし | |
| Director of Investor Relations | no data | データなし | データなし | |
| Senior VP | 2.3yrs | データなし | データなし |
4.4yrs
平均在職期間
59yo
平均年齢
経験豊富な経営陣: LUCDの経営陣は 経験豊富 であると考えられます ( 4.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 8yrs | US$897.00k | 1.91% $ 3.9m | |
| Independent Vice Chairman of the Board & Lead Independent Director | 4.8yrs | US$230.57k | 0.18% $ 361.0k | |
| Independent Director | 4.6yrs | US$278.07k | 0.17% $ 342.9k | |
| Independent Director | 5.1yrs | US$268.07k | 0.17% $ 342.9k | |
| Independent Director | 2yrs | US$253.57k | 0.41% $ 843.6k | |
| Independent Director | 8yrs | US$238.07k | 0.21% $ 433.5k | |
| Independent Director | 3.8yrs | US$248.07k | 0.12% $ 252.3k | |
| Chair of Medical Advisory Board | 8yrs | データなし | データなし | |
| Member of Medical Advisory Board | 8yrs | データなし | データなし | |
| Member of Medical Advisory Board | 5.8yrs | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし |
5.5yrs
平均在職期間
70yo
平均年齢
経験豊富なボード: LUCDの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/24 12:45 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Lucid Diagnostics Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |